| Title | Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia. | | Author(s) | Kim T, Kim SH, Park KH, Cho OH, Sung H, Kim MN, Choi SH, Jeong JY, Woo JH, Kim YS, Lee SO | | Institution | Department of Infectious Diseases, Asan Medical Center, 388-1 Pungnap-2dong, Songpa-gu, Seoul, 138-736, Korea. | | Source | J Infect Chemother 2009 Oct; 15(5):343-6. | | Abstract | There are limited data on the efficacy of alternative regimens for treating patients with pneumocystis pneumonia (PCP). We compared the efficacy of clindamycin-primaquine (C-P) with that of pentamidine as a secondline treatment for PCP. Among 91 patients receiving trimethoprim-sulfamethoxazole (TMP-SMX) as a first-line treatment for PCP, 31 (34%) did not respond and 7 (8%) had adverse reactions. Fourteen patients received C-P and 9 received pentamidine as a second-line regimen because of treatment failure or an adverse reaction to TMP-SMX. The response rate of patients to C-P was higher than the response rate to pentamidine (9/14; 64% vs 1/9; 11%; P = 0.03). | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19856077 |
|
